je.st
news
Tag: merck
Ashland Takes Entire Fourth Floor at Former Merck & Co. Property in Parsippany
2013-03-28 01:34:00| National Real Estate Investor
Ashland Specialty Ingredients, a commercial unit of Ashland Inc., has signed a 75,000-sq.-ft. lease to occupy the entire fourth floor at 56 Livingston Ave. Building ownership, Mountain Development and Square Mile Capital Management, were represented by Jones Lang LaSalles Craig Eisenhardt, Jonathan Meisel, Robert Ryan and Peter Politi. Ashland was represented by Colliers Internationals Bryn Cinque and James Bailey in the transaction. read more
Tags: in
property
entire
takes
Merck: FDA reviewing tablet to eliminate allergy
2013-03-27 18:30:45| Biotech - Topix.net
Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving the sneezing and itching.
Tags: eliminate
reviewing
tablet
allergy
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
2013-03-27 13:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet (AIT) has been accepted for review by the U.S. Food and Drug Administration (FDA). In March, the company also submitted a BLA to the FDA for its investigational ragweed pollen (Ambrosia artemisiifolia) AIT. Language: English Contact HTML: MerckMedia:Pam Eisele, (908) 423-5042Tracy Ogden, (267) 305-2301orInvestors:Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
grass
Merck anesthesia-reversal agent faces new delay
2013-03-15 17:56:34| Biotech - Topix.net
The Food and Drug Administration will not complete its review of Merck & Co's experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three-month delay, the drugmaker.
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimers Disease
2013-03-13 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & AUSTIN, Texas Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Mercks Lead Investigational Medicine for Alzheimers Disease WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). Language: English Contact HTML: Media Contacts:MerckCaroline Lappetito, 267-305-7639orLuminexMimi Torrington, 512-219-8020mtorrington@luminexcorp.comorInvestor Contacts:MerckCarol Ferguson, 908-423-4465orLuminexMatt Scalo, 512-336-3587mscalo@luminexcorp.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LMNX Exchange: NASDAQ read more
Tags: support
enter
development
program
Sites : [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] next »